lansoprazole has been researched along with Fibrosis in 2 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we investigated the effects of lansoprazole on cardiac hypertrophy and heart failure, as well as the underlying mechanisms." | 7.96 | Lansoprazole alleviates pressure overload-induced cardiac hypertrophy and heart failure in mice by blocking the activation of β-catenin. ( Bin, J; Chen, L; Chen, Z; Kitakaze, M; Li, Y; Liao, W; Liao, Y; Lin, H; Wang, Q; Wang, Y; Zheng, C; Zhu, H; Zhu, Y, 2020) |
| " Here, we investigated the effects of lansoprazole on cardiac hypertrophy and heart failure, as well as the underlying mechanisms." | 3.96 | Lansoprazole alleviates pressure overload-induced cardiac hypertrophy and heart failure in mice by blocking the activation of β-catenin. ( Bin, J; Chen, L; Chen, Z; Kitakaze, M; Li, Y; Liao, W; Liao, Y; Lin, H; Wang, Q; Wang, Y; Zheng, C; Zhu, H; Zhu, Y, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, H | 1 |
| Li, Y | 1 |
| Zhu, H | 1 |
| Wang, Q | 1 |
| Chen, Z | 1 |
| Chen, L | 1 |
| Zhu, Y | 1 |
| Zheng, C | 1 |
| Wang, Y | 1 |
| Liao, W | 1 |
| Bin, J | 1 |
| Kitakaze, M | 1 |
| Liao, Y | 1 |
| Dohil, R | 1 |
| Newbury, R | 1 |
| Fox, L | 1 |
| Bastian, J | 1 |
| Aceves, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Trial Comparing Fluticasone Plus Omeprazole With Fluticasone Alone for Eosinophilic Esophagitis[NCT03781596] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-10-02 | Recruiting | ||
| Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial[NCT00638456] | Phase 2 | 32 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Prospective Pilot Study Evaluating the Efficacy of Low-Dose Topical Steroids in Maintaining Histologic Remission of Eosinophilic Esophagitis in Children[NCT05309590] | 50 participants (Anticipated) | Observational [Patient Registry] | 2014-05-31 | Active, not recruiting | |||
| Phenotypic Characterization of Pediatric Patients With Esophageal Eosinophilia and Biomarkers Investigation for the Diagnosis of Eosinophilic Esophagitis[NCT03069573] | 110 participants (Actual) | Observational [Patient Registry] | 2015-01-01 | Completed | |||
| A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children[NCT01458418] | 4 participants (Actual) | Interventional | 2011-12-31 | Terminated (stopped due to Inability to complete enrollment due to difficulty in finding subjects) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Repeat endoscopy was undertaken using the Olympus P160 endoscope (by RD) at 3 months of treatment. (NCT00638456)
Timeframe: 3 Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Viscous Budesonide Plus Prevacid | 13 |
| Placebo Plus Prevacid | 0 |
"Total score was based on the following symptoms:~Heartburn/regurgitation Abdominal pain Nausea/vomiting Anorexia/early satiety Dysphagia Symptom induced nocturnal wakening Gastrointestinal bleeding~Each symptom could score 0-2 for a maximum score for 14 points. The lower the score the milder the symptoms and the higher the score the more severe symptoms." (NCT00638456)
Timeframe: Baseline and 3 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 3 months | |
| Oral Viscous Budesonide Plus Prevacid | 3.5 | 1.2 |
| Placebo Plus Prevacid | 2.7 | 1.8 |
"Endoscopy scoring tool took into account the following categories:~Mucosal pallor/reduced vasculature Linear furrows/mucosal thickening White plaques Concentric rings/stricture Friability/tissue-paper mucosa Histology scoring tools Epithelial histology score Peak eosinophil count~Each category could score 0-3 for a total maximum score of 15. The higher the score the worse the disease." (NCT00638456)
Timeframe: Baseline and 3 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 3 months | |
| Oral Viscous Budesonide Plus Prevacid | 4.6 | 1.5 |
| Placebo Plus Prevacid | 7.8 | 5.4 |
Eosinophils/high powered field(hpf) in the mid esophagus will be measured after 12 weeks of therapy. (NCT01458418)
Timeframe: 12 weeks
| Intervention | Eosinophils/HPF (Mean) |
|---|---|
| Subjects Whose Arm is Unknown Due to Not Being Unblinded | 8 |
1 trial available for lansoprazole and Fibrosis
| Article | Year |
|---|---|
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Anti-Inflammatory Agents; | 2010 |
1 other study available for lansoprazole and Fibrosis
| Article | Year |
|---|---|
Lansoprazole alleviates pressure overload-induced cardiac hypertrophy and heart failure in mice by blocking the activation of β-catenin.
Topics: Animals; Aorta; beta Catenin; Cell Proliferation; Cells, Cultured; Constriction; Disease Models, Ani | 2020 |